Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) closed the day trading at $16.53 down -1.08% from the previous closing price of $16.71. In other words, the price has decreased by -$1.08 from its previous closing price. On the day, 8.35 million shares were traded. TEVA stock price reached its highest trading level at $16.77 during the session, while it also had its lowest trading level at $16.45.
Ratios:
For a better understanding of TEVA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.10. For the most recent quarter (mrq), Quick Ratio is recorded 0.74 and its Current Ratio is at 1.03. In the meantime, Its Debt-to-Equity ratio is 2.71 whereas as Long-Term Debt/Eq ratio is at 2.64.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $24.
On May 28, 2025, Truist started tracking the stock assigning a Buy rating and target price of $25.
JP Morgan Upgraded its Neutral to Overweight on May 12, 2025, while the target price for the stock was maintained at $23.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 12 ’25 when Kalif Eliyahu Sharon sold 55,775 shares for $17.08 per share. The transaction valued at 952,464 led to the insider holds 403,288 shares of the business.
Kalif Eliyahu Sharon bought 55,775 shares of TEVA for $952,466 on Jun 12 ’25. On Jun 03 ’25, another insider, Shields Matthew, who serves as the EVP, Global Operations of the company, sold 6,206 shares for $17.02 each. As a result, the insider received 105,628 and left with 9,989 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TEVA now has a Market Capitalization of 18989004800 and an Enterprise Value of 34472046592. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.14 while its Price-to-Book (P/B) ratio in mrq is 3.03. Its current Enterprise Value per Revenue stands at 2.075 whereas that against EBITDA is 7.743.
Stock Price History:
The Beta on a monthly basis for TEVA is 0.63, which has changed by -0.04340279 over the last 52 weeks, in comparison to a change of 0.11844492 over the same period for the S&P500. Over the past 52 weeks, TEVA has reached a high of $22.80, while it has fallen to a 52-week low of $12.47. The 50-Day Moving Average of the stock is -2.79%, while the 200-Day Moving Average is calculated to be -4.94%.
Shares Statistics:
Over the past 3-months, TEVA traded about 11.72M shares per day on average, while over the past 10 days, TEVA traded about 9733790 shares per day. A total of 1.15B shares are outstanding, with a floating share count of 1.15B. Insiders hold about 0.01% of the company’s shares, while institutions hold 62.85% stake in the company. Shares short for TEVA as of 1749772800 were 39997484 with a Short Ratio of 3.41, compared to 1747267200 on 38696395. Therefore, it implies a Short% of Shares Outstanding of 39997484 and a Short% of Float of 3.5000000000000004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0The stock’s 5-year Average Dividend Yield is 2.95.
Earnings Estimates
The dynamic stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.72, with high estimates of $0.74 and low estimates of $0.68.
Analysts are recommending an EPS of between $2.65 and $2.48 for the fiscal current year, implying an average EPS of $2.55. EPS for the following year is $2.76, with 11.0 analysts recommending between $2.85 and $2.64.
Revenue Estimates
7 analysts predict $4.3B in revenue for the current quarter. It ranges from a high estimate of $4.43B to a low estimate of $4.2B. As of the current estimate, Teva- Pharmaceutical Industries Ltd. ADR’s year-ago sales were $4.16BFor the next quarter, 7 analysts are estimating revenue of $4.45B. There is a high estimate of $4.57B for the next quarter, whereas the lowest estimate is $4.32B.
A total of 10 analysts have provided revenue estimates for TEVA’s current fiscal year. The highest revenue estimate was $17.15B, while the lowest revenue estimate was $16.82B, resulting in an average revenue estimate of $16.97B. In the same quarter a year ago, actual revenue was $16.54BBased on 10 analysts’ estimates, the company’s revenue will be $17.01B in the next fiscal year. The high estimate is $17.43B and the low estimate is $16.67B.
